ADCETRIS® (brentuximab vedotin) Prescribing Information

ADCETRIS® (brentuximab vedotin) as a treatment option for your eligible adult patients with CD30+ cutaneous T-cell lymphoma

ADCETRIS is indicated for use in CD30+ cutaneous T-cell lymphoma (CTCL) in adult patients after at least 1 prior systemic therapy.1

Funding status

ADCETRIS is NICE approved and SMC accepted as an option for adult patients with CD30+ CTCL.2,3 Patients must be diagnosed with advanced CTCL, defined as mycosis fungoides stage IIB or above, primary cutaneous anaplastic large cell lymphoma, or Sézary syndrome, and have received at least one prior systemic therapy.2,3

For more information on NHS funding of ADCETRIS, please refer to the Blueteq criteria where applicable.4

ADCETRIS key safety information

Please consult the Summary of Product Characteristics before prescribing ADCETRIS and for full information about dosing, administration, contraindications, special warnings and tolerability profile.

When used as monotherapy (across HL, sALCL and CTCL studies), the most frequent adverse reactions (≥10%) were infections, peripheral sensory neuropathy, nausea, fatigue, diarrhoea, pyrexia, neutropenia, upper respiratory tract infection, arthralgia, rash, cough, vomiting, pruritus, peripheral motor neuropathy, infusion-related reactions, constipation, dyspnoea, myalgia, weight decreased, and abdominal pain.1

A healthcare professional wearing a white coat and stethoscope is seated at a desk, holding a pen and speaking with another person across the table in a clinical setting.

Further information

Explore three unique CTCL case studies authored by Professor Julia Scarisbrick, Dr Dima El-Sharkawi and Dr Stella Williams.

Click here for the infographic

CTCL, cutaneous T-cell lymphoma; HL, Hodgkin lymphoma; NICE, National Institute for Health and Care Excellence; sALCL, systemic anaplastic large cell lymphoma; SMC, Scottish Medicines Consortium. 

1. ADCETRIS Summary of Product Characteristics. 2. NICE TA577. Available at: www.nice.org.uk/guidance/ta577/chapter/1-Recommendation; 3. SMC 2229. Available at: scottishmedicines.org.uk/medicines-advice/brentuximab-adcetris-full-smc2229; 4. Cancer Drugs Fund List. Available at: https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/.

To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.